Turning Point Therapeutics Inc. (TPTX) PT Raised to $155 at Wedbush, Following Earnings
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten raised the price target on Turning Point Therapeutics Inc. (NASDAQ: TPTX) to $155.00 (from $136.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades L'Oreal SA (OR:FP) (LRLCY) to Conviction Buy
- Longtop Financial (LFT) PT Raised to $4.25 at JMP Securities, Ahead Of Earnings
- Credit Suisse Downgrades Gigadevice Semiconductor Beijing (603986:CH) to Neutral